Olanzapine 5 mg for Nausea and Vomiting in Patients with Nasopharyngeal Carcinoma Receiving Cisplatin-Based Concurrent Chemoradiotherapy

PURPOSE: To explore the efficacy and safety of adding olanzapine (5 mg or 10 mg) to 5-hydroxytryptamine type 3 receptor antagonists (5-HT(3) RA), neurokinin-1 receptor antagonists (NK1 RA), and dexamethasone for nausea and vomiting in patients with nasopharyngeal carcinoma (NPC) receiving cisplatin-...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jun, Li, Tao, Lin, Li-E, Lin, Qin, Wu, San-Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959964/
https://www.ncbi.nlm.nih.gov/pubmed/35356256
http://dx.doi.org/10.1155/2022/9984738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959964/
https://www.ncbi.nlm.nih.gov/pubmed/35356256
http://dx.doi.org/10.1155/2022/9984738

Ejemplares similares